Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Common Equity (2016 - 2025)

Historic Common Equity for Haemonetics (HAE) over the last 16 years, with Q4 2025 value amounting to $911.5 million.

  • Haemonetics' Common Equity rose 50.63% to $911.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $911.5 million, marking a year-over-year increase of 50.63%. This contributed to the annual value of $820.8 million for FY2025, which is 1449.26% down from last year.
  • As of Q4 2025, Haemonetics' Common Equity stood at $911.5 million, which was up 50.63% from $849.2 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Common Equity ranged from a high of $960.0 million in Q1 2024 and a low of $677.1 million during Q3 2021
  • In the last 5 years, Haemonetics' Common Equity had a median value of $835.0 million in 2025 and averaged $824.9 million.
  • In the last 5 years, Haemonetics' Common Equity soared by 2462.25% in 2021 and then tumbled by 1449.26% in 2025.
  • Over the past 5 years, Haemonetics' Common Equity (Quarter) stood at $698.5 million in 2021, then rose by 11.08% to $776.0 million in 2022, then grew by 21.57% to $943.3 million in 2023, then decreased by 3.86% to $906.9 million in 2024, then grew by 0.51% to $911.5 million in 2025.
  • Its Common Equity stands at $911.5 million for Q4 2025, versus $849.2 million for Q3 2025 and $882.3 million for Q2 2025.